Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes

Blood

Volumn 105, Issue 6, 2005, Pages 2258-2265

  Stanzani, Marta ^b   Orciuolo, Enrico ^b   Lewis, Russell ^b   Kontoyiannis, Dimitrios P ^b   Martins, Sergio L R ^b   St John, Lisa S ^b   Komanduri, Krishna V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD83 ANTIGEN; CYTOKINE; FUNGUS ANTIGEN; GLIOTOXIN; STAPHYLOCOCCUS ENTEROTOXIN B;

ANTIGEN PRESENTING CELL; APOPTOSIS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DENDRITIC CELL; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; LYMPHOCYTE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TOXIN SYNTHESIS;

EID: 15244354736     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3421     Document Type: Conference Paper

References (45)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803.
2. Denning DW, Anderson MJ, Turner G, Latge JP, Bennett JW. Sequencing the Aspergillus fumigatus genome. Lancet Infect Dis. 2002;2:251-253.
3. Jantunen E, Anttila VJ, Ruutu T. Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress? Bone Marrow Transplant. 2002;30:925-929.
4. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32:1319-1324.
5. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12:310-350.
6. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358-4366.
7. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002;29:15-19.
8. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
9. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459-1466.
10. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 1997;19:801-808.
11. Roilides E, Katsifa H, Walsh TJ. Pulmonary host defenses against Aspergillus fumigatus. Res Immunol. 1998;149:454-465.
12. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood. 2002;100:4521-4528.
13. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol. 2000; 165:381-388.
14. Cenci E, Mencacci A, Fe d'Ostiani C, et al. Cytokine-and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis. 1998;178:1750-1760.
15. Waring P, Beaver J. Gliotoxin and related epipolythiodioxopiperazines. Gen Pharmacol. 1996;27:1311-1316.
16. Eichner RD, Al Salami M, Wood PR, Mullbacher A. The effect of gliotoxin upon macrophage function. Int J Immunopharmacol. 1986;8:789-797.
17. Mullbacher A, Eichner RD. Immunosuppression in vitro by a metabolite of a human pathogenic fungus. Proc Natl Acad Sci U S A. 1984;81:3835-3837.
18. Watanabe A, Kamei K, Sekine T, et al. Immunosuppressive substances in Aspergillus fumigatus culture filtrate. J Infect Chemother. 2003;9:114-121.
19. Yamada A, Kataoka T, Nagai K. The fungal metabolite gliotoxin: immunosuppressive activity on CTL-mediated cytotoxicity. Immunol Lett. 2000;71:27-32.
20. Pahl HL, Krauss B, Schulze-Osthoff K, et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med. 1996;183:1829-1840.
21. Tomee JF, Kauffman HF. Putative virulence factors of Aspergillus fumigatus. Clin Exp Allergy. 2000;30:476-484.
22. Mullbacher A, Moreland AF, Waring P, Sjaarda A, Eichner RD. Prevention of graft-versus-host disease by treatment of bone marrow with gliotoxin in fully allogeneic chimeras and their cytotoxic T cell repertoire. Transplantation. 1988;46:120-125.
23. Sutton P, Moreland A, Hutchinson IV, Mullbacher A. Investigation of the potential use of immunosuppressive agent gliotoxin in organ transplantation. Transplantation. 1995;60:900-902.
24. Lewis RE, Wiederhold NP, Chi J, et al. Detection of gliotoxin in experimental and human aspergillosis. Infect Immun. 2005;73:635-637.
25. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998;4:953-956.
26. + T cells. Blood. 2002;100:3690-3697.
27. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods. 1995; 184:39-51.
28. Bozza S, Gaziano R, Spreca A, et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol. 2002;168:1362-1371.
29. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2004;4:1-23.
30. + T cell counts and recurrent retinitis. J Infect Dis, 2001;183: 1285-1289.
31. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1 specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Mat Med. 1999; 5:518-525.
32. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis. 2000;181:859-866.
33. Maino VC, Maecker HT. Cytokine flow cytometry: a multiparametric approach for assessing cellular immune responses to viral antigens. Clin Immunol. 2004;110:222-231.
34. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell. 1996;87:565-576.
35. Arlt A, Vorndamm J, Breitenbroich M, et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 2001;20: 859-868.
36. Baust H, Schoke A, Brey A, et al. Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-kappaB independent mechanisms. Oncogene. 2003;22:8786-8796.
37. Daly P, Verhaegen S, Clynes M, Kavanagh K. Culture filtrates of Aspergillus fumigatus induce different modes of cell death in human cancer cell lines. Mycopathologia. 1999;146:67-74.
38. Sutton P, Beaver J, Waring P. Evidence that gliotoxin enhances lymphocyte activation and induces apoptosis by effects on cyclic AMP levels. Biochem Pharmacol. 1995;50:2009-2014.
39. Waring P, Eichner RD, Mullbacher A, Sjaarda A. Gliotoxin induces apoptosis in macrophages unrelated to its antiphagocytic properties. J Biol Chem. 1988;263:18493-18499.
40. Upperman JS, Potoka DA, Zhang XR, Wong K, Zamora R, Ford HR. Mechanism of intestinal-derived fungal sepsis by gliotoxin, a fungal metabolite. J Pediatr Surg. 2003;38:966-970.
41. Kweon YO, Paik YH, Schnabl B, Qian T, Lemasters JJ, Brenner DA. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol. 2003;39:38-46.
42. Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology. 2001;121: 685-698.
43. Hurne AM, Chai CL, Waring P. Inactivation of rabbit muscle creatine kinase by reversible formation of an internal disulfide bond induced by the fungal toxin gliotoxin. J Biol Chem. 2000;275:25202-25206.
44. Braithwaite AW, Eichner RD, Waring P, Mullbacher A. The immunomodulating agent gliotoxin causes genomic DNA fragmentation. Mol Immunol. 1987;24:47-55.
45. Bernardo PH, Brasch N, Chai CL, Waring P. A novel redox mechanism for the glutathione-dependent reversible uptake of a fungal toxin in cells. J Biol Chem. 2003;278:46549-46555.